Stock Pick

  • Christine Daley, Lehman’s Star Distressed Debt Analyst, Dies

    Christine Daley, Lehman’s Star Distressed Debt Analyst, Dies(Bloomberg) — Christine Daley, a veteran analyst who headed Lehman Brothers’ distressed debt team before the firm’s collapse in 2008, has died.The New York-based investment bank Seaport Global Securities LLC., Daley’s most recent employer, confirmed her death on Sunday. “The firm extends our deepest condolences to Christine’s family,” a spokesperson told Bloomberg News. No cause of death was given. Daley was born in July 1958, according to public records.“Christine was our star research analyst,” Jay McDermott, now the co-head of cross-asset at Cowen Inc., said of his time working alongside Daley at the brokerage firm Bear Stearns Cos. “The whole bank loan market really developed around mid-90s, and Christine was a pioneer and a big name in the business,” McDermott said in a phone interview on Sunday.A graduate of the College of New Rochelle and NYU Stern School of Business, Daley joined Bear Stearns in the high yield and bankruptcy department and worked there until 1993. She later became a managing director at Lehman Brothers, where she led the distressed debt and special situations proprietary desk, and oversaw distressed debt and high yield research.After the collapse of Lehman Brothers during the global financial crisis, Daley joined Oak Hill Advisors in 2009 as managing director of the firm’s investment team. In 2011, she joined River Birch Capital, a hedge fund co-founded by ex-Lehman President and COO Bart McDade that shuttered in late 2018, before switching to Seaport Global.Larry McDonald, the founder of investment newsletter Bear Traps Report and a former colleague of Daley at Lehman, said she was a “true Hall-of-Famer” in the distressed investing universe.In his 2010 book “A Colossal Failure of Common Sense: The Inside Story of the Collapse of Lehman Brothers,” he recalled the time that Daley sensed financial problems at the electricity company Calpine and proposed a massive short position that “took a lot of guts.” Her recommendation would end up making over $190 million for Lehman.McDermott remembered Daley’s passion and energy for finding opportunities, recalling that she once got the team excited to work on sourcing a deal late into the night before Thanksgiving.“When she was excited, you were excited. She was one of those people who made everyone on the team a better player,” McDermott said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

    from Yahoo Finance https://ift.tt/2WYriv2

  • ASX 200 Weekly Wrap: ASX has week of high volatility

    laptop, newspaper, ipad, coffee and hands holding iphone

    The S&P/ASX 200 Index (ASX: XJO) has endured one of its more volatile weeks in recent months last week as ASX 200 bulls and bears struggled for control. The ASX 200 remains above the psychologically-important 6,000 point threshold, but only just — closing at 6,024 points last Friday. That was despite the ASX 200 touching a low 0f 5,991 points on Monday, and a high of 6,156 points on Wednesday.

    The latter represents the highest point the index has touched since the coronavirus pandemic smashed global markets back in March, giving you some idea of how wildly the markets were swinging last week. Between Monday afternoon and Wednesday morning, ASX 200 shares gained more than 2.7%. Conversely, between Wednesday morning and Thursday afternoon, the markets gave back around 1.5% of those gains.

    By market close on Friday, the ASX 200 ‘only’ lost 0.16% for the week. But it was open warfare between ASX bulls and bears in the meantime.

    Vaccines and deficits

    Sentiment surrounding possible developments of a coronavirus treatment or vaccine, as well as an extension of government stimulus programs, were the primary positive influences for the ASX last week. We heard from both the United Kingdom-based company AstraZeneca and the United States-based Moderna that progress is being made on a potential treatment or vaccination for the coronavirus, which is of course extremely exciting news.

    On the other hand, coronavirus cases in Victoria continue to be at highly concerning levels, and the situation in New South Wales also remains fluid. This put a dampener on the vaccine excitement from earlier in the week and was the main factor pulling the ASX 200 back to Earth from Wednesday onwards.

    We also got a sobering fiscal update from the Treasurer last Thursday. Markets initially applauded the government’s decision on Tuesday to extend its JobKeeper and coronavirus supplement safety net payments until at least March 2021 (albeit with reduced and tiered payment rates and tightened eligibility). But the reality of an almost-unfathomable $85.8 billion budget deficit for the 2020 financial year (and a projected deficit of $184.5 billion in FY21) also began to sink in.

    All in all, it was a week of high drama in multiple arenas last week, and the market responded with some drama of its own in turn.

    How did the markets end the week?

    As I flagged earlier, the ASX 200 ended the week 0.16% in the red after starting out at 6,033.6 points and closing on Friday at 6,024 points. Monday saw a 0.5% slump, whereas Tuesday brought the punch back to the party with a 2.6% gain. But Wednesday saw the bears regain control with a 1.3% slide. Thursday saw a modest 0.3% gain, but Friday sealed the week’s red fate with another 1.1% loss.

    Meanwhile, the All Ordinaries (INDEXASX: XAO) also had a flat week, starting at 6,144.9 points and finishing at 6,148 points for a week-to-week gain of 0.05%.

    Which ASX 200 shares were the biggest winners and losers?

    Time for things to get interesting with our weekly winners and losers. As per usual, we shall start with the losers:

    Worst ASX 200 losers

     % loss for the week
    Alumina Limited (ASX: AWC)

    (7.2%)
    Cooper Energy Ltd (ASX: COE)

    (7.1%)
    Western Areas Ltd (ASX: WSA)

    (6.6%)
    TPG Telecom Ltd (ASX: TPG)

    (6.1%)

    Well, today we have 2 ‘hero-to-zero’ shares (not literally zero) in Alumina and Cooper Energy, who both made the previous week’s winners list. There appeared to be no major news out of either company last week, so we can probably put these large losses down to investors taking some profits off the table after strong gains the week prior.

    Western Areas is a nickel producer who gave a disappointing market update on Friday.

    The newly merged TPG was also on investors’ hit list. Perhaps, with nothing to look forward to (specifically in the mergers and special dividends department), investors have gotten bored of the newly-wed telco.

    Now let’s take a look at the winners from last week:

    Best ASX 200 gainers

     % gain for the week
    Resolute Mining Limited  (ASX: RSG)

    17.2%
    AP Eagers Ltd (ASX: APE)

    16.8%
    Orocobre Limited (ASX: ORE)

    13.2%
    QBE Insurance Group Ltd (ASX: QBE)

    11%

    ASX gold miner Resolute takes out last week’s crown with a hefty gain. Investors were keen to get hold of Resolute shares after the company reported a positive quarterly update with increased gold production. A near-record high gold price wouldn’t have hurt either.

    Car dealership owner AP Eagers was also in favour after some positive brokering coverage.

    Lithium miner Orocobre was also a buyer target, despite this company’s volatile performance in 2020 so far and no real news being released last week. Orocobre shares are now up more than 70% since May, so perhaps this is a case of investors jumping on an accelerating train here.

    What is this week looking like for the ASX 200?

    It continues to be a moving arena for ASX shares, so (frankly) who knows what twists and turns this week will bring. For a start, all eyes will continue to be on coronavirus case levels in Australia (and particularly Victoria) as we start a new week.

    The Aussie dollar also continues to shine, so it will be noteworthy to see whether it climbs above its current ~71 US cents level this week.

    Turning to ASX 200 shares, we saw some fairly heavy selling of ASX bank shares like Commonwealth Bank of Australia (ASX: CBA) on Friday, so it will be interesting to see how the banks open this week. Insurance giant Insurance Australia Group Ltd (ASX: IAG) announced it would be the latest ASX 200 share to cancel its dividend on Friday – highlighting what a perilous year 2020 has been for dividend investors so far.

    And I’ll personally be keeping an eye on the gold price as it approaches the all-time high of US$1,920 per ounce it hit back in 2011.

    Before we go, here is a look at how the major ASX 200 blue chip shares are looking as we prepare for the new week:

    ASX 200 company

    Trailing P/E ratio

    Last share price

    52-week high

    52-week low
    CSL Limited (ASX: CSL)

    44.65

    $277.02

    $342.75

    $215.24
    Commonwealth Bank of Australia (ASX: CBA)

    13.22

    $72.86

    $91.05

    $53.44
    Westpac Banking Corp (ASX: WBC)

    13.33

    $17.76

    $30.05

    $13.47
    National Australia Bank Ltd. (ASX: NAB)

    16.14

    $17.98

    $30.00

    $13.20
    Australia and New Zealand Banking Group Limited (ASX: ANZ)

    12.45

    $18.29

    $28.79

    $14.10
    Woolworths Group Ltd (ASX: WOW)

    19.23

    $38.63

    $43.96

    $32.12
    Wesfarmers Ltd (ASX: WES)

    24.04

    $46.36

    $47.42

    $29.75
    BHP Group Ltd (ASX: BHP) 14.24

    $37.08

    $41.98

    $24.05
    Rio Tinto Limited (ASX: RIO)

    15.06

    $102.92

    $107.79

    $72.77
    Coles Group Ltd (ASX: COL)

    20.00

    $17.78

    $18.32

    $13.10
    Telstra Corporation Ltd (ASX: TLS)

    19.21

    $3.33

    $4.01

    $2.87
    Transurban Group (ASX: TCL)

    162.03

    $13.70

    $16.44

    $9.10
    Sydney Airport Holdings Pty Ltd (ASX: SYD)

    30.18

    $5.40

    $9.30

    $4.37
    Newcrest Mining Limited (ASX: NCM)

    33.98

    $34.60

    $38.87

    $20.70
    Woodside Petroleum Limited (ASX: WPL)

    40.82

    $20.99

    $36.28

    $14.93
    Macquarie Group Ltd (ASX: MQG)

    14.80

    $125.79

    $152.35

    $70.45

    And finally, here is the lay of the land for some leading market indicators:

    •     S&P/ASX 200 (XJO) at 6,024 points
    •     All Ordinaries (XAO) at 6,148 points
    •     Dow Jones Industrial Average at 26,469.89 points after falling 0.68% on Friday night (our time)
    •     Gold (Spot) swapping hands for US$1,901.30 per troy ounce
    •     Iron ore asking US$105.59 per tonne
    •     Crude oil (Brent) trading at US$43.42 per barrel
    •     Crude oil (WTI) going for US$41.34 per barrel
    •     Australian dollar buying 71.03 US cents
    •    10-year Australian Government bonds yielding 0.86% per annum

    Foolish takeaway

    After last week’s swings, I’m reminded how much short-term sentiment can sway the ASX 200 sharemarket — and equally how little these short-term swings really matter in the long-run. So don’t let volatility get you down Fools! It’s our constant reminder that the share market is a place where cool heads always prevail in the end. So, as always, stay safe out there, stay rational and stay Foolish!

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    See The 5 Stocks

    *Returns as of June 30th

    More reading

    Sebastian Bowen owns shares of National Australia Bank Limited, Newcrest Mining Limited, and Telstra Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited and Telstra Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET, Transurban Group, Wesfarmers Limited, and Woolworths Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post ASX 200 Weekly Wrap: ASX has week of high volatility appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3jBBtzr

  • 5 things to watch on the ASX 200 on Monday

    ASX share

    On Friday the S&P/ASX 200 Index (ASX: XJO) finished the week on a disappointing note. The benchmark index fell 1.15% to 6,024 points.

    Will the market be able to bounce back from this on Monday? Here are five things to watch:

    ASX 200 set to drop lower.

    The ASX 200 looks set to drop lower this morning after a poor finish to the week on Wall Street. According to the latest SPI futures, the benchmark index is expected to open the week 27 points or 0.45% lower. On Wall Street the Dow Jones fell 0.7%, the S&P 500 dropped 0.6%, and the Nasdaq fell 0.9%.

    Oil prices edge higher.

    Energy producers such as Santos Ltd (ASX: STO) and Woodside Petroleum Limited (ASX: WPL) could start the week with a small gain. According to Bloomberg, the WTI crude oil price climbed 0.55% to US$41.29 a barrel and the Brent crude oil price rose 0.1% to US$43.34 a barrel. This was the third week out of four that oil prices have recorded weekly gains.

    Gold price breaks through US$1,900 mark.

    Gold miners including Newcrest Mining Limited (ASX: NCM) and Northern Star Resources Ltd (ASX: NST) could be on the rise on Monday after the gold price strengthened further. According to CNBC, the spot gold price rose 0.4% to US$1,925.20 an ounce. The gold price closed at a record high amid rising tensions between the U.S. and China.

    Non-bank financial shares to buy.

    Analysts at Goldman Sachs have been looking through non-bank financial shares ahead of earnings season and are recommending which ones to buy and which ones to sell. Top of the buy list is the QBE Insurance Group Ltd (ASX: QBE) share price with a conviction buy rating and an $11.52 price target. This price target implies potential upside of 11% excluding dividends. It believes QBE is well positioned to capitalise on the hardening cycle.

    Non-bank financial shares to sell.

    At the bottom of Goldman Sachs’ list among the non-bank financials is the ASX Ltd (ASX: ASX) share price. It has a sell rating and $70.29 price target on the stock exchange operator’s shares. This price target implies potential downside of 16% for its shares. It is bearish on ASX Ltd due to emerging rates business headwinds and its peak valuation belief.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    See The 5 Stocks

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 5 things to watch on the ASX 200 on Monday appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3jJ86LC

  • Opinion: Trump’s Response to Urban Chaos

    Opinion: Trump's Response to Urban ChaosJournal Editorial Report: Is he off-base, or on the right track? Images: Zuma Press/Getty Images Composite: Mark Kelly

    from Yahoo Finance https://ift.tt/2P1t5uI

  • Opinion: Trump Reboots His Virus Briefings

    Opinion: Trump Reboots His Virus BriefingsJournal Editorial Report: Boasting is out, information is in. Image: Chip Somodevilla/Getty Images

    from Yahoo Finance https://ift.tt/2OXdXPb

  • Buy these blue chip ASX dividend shares for income

    mining dividend shares

    If you’re planning to buy some dividend shares this week, then you might want to consider the ones listed below.

    I think these ASX dividend shares are top option for income investors right now. Here’s why:

    Australia and New Zealand Banking GrpLtd (ASX: ANZ)

    Rather than put money into its savings accounts or term deposits, I think investors would be better off buying this banking giant’s shares. At approximately 0.9x estimated FY 2021 book value, I think ANZ’s shares could be great value after their sizeable pullback this year.

    And while the bank will almost certainly have to cut its dividend further in FY 2021, I believe the recent share price weakness means that it will still provide investors with an above-average yield. I currently expect ANZ to pay its shareholders a partially franked dividend of $1.05 per share in FY 2021. Based on the latest ANZ share price, this will provide investors with a very attractive forward 5.7% yield.

    Wesfarmers Ltd (ASX: WES)

    Another ASX dividend share to consider buying is this conglomerate. I think Wesfarmers is a great option due to its positive long term outlook thanks to its collection of quality brands. These brands include the likes of Bunnings, Kmart, Target, ecommerce company Catch Group, and a collection of industrial businesses. 

    In addition to this, the company is sitting on a sizeable cash balance and looks very likely to put it to work with value accretive acquisitions in the near term. If these potential acquisitions are a success, it could give its growth an additional boost. I estimate that the company will be paying its shareholders a dividend of approximately $1.46 per share in FY 2021. Based on the current Wesfarmers share price, this equates to a fully franked 3.15% dividend yield.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    See The 5 Stocks

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Buy these blue chip ASX dividend shares for income appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/39v2P5r

  • New U.S. home sales jump 13.8% in June, topping estimates

    New U.S. home sales jump 13.8% in June, topping estimates On Friday, the U.S. Commerce Department reported that sales of new U.S. single-family homes jumped to a near 13-year high in June. The news comes as home seller profits reached another post-recession high in Q2, according to ATTOM Data Solutions, with home sellers nationwide seeing gains of $75,971 on the typical sale, representing a 36.3% return on investment compared to the original purchase price. Todd Teta, Chief Product & Technology Officer at ATTOM Data Solutions, joins The Final Round to break down the company’s report on home seller profits in the second quarter, and discuss his outlook for the housing market.

    from Yahoo Finance https://ift.tt/300HCgT

  • Why this expert says the ‘do nothing’ approach to retirement planning is not good advice amid market uncertainty

    Why this expert says the ‘do nothing’ approach to retirement planning is not good advice amid market uncertainty Farnoosh Torabi, Financial Expert and Contributing Editor at NextAdvisor.com, joined Yahoo Finance’s ‘The Final Round’ to discuss the biggest mistakes young people make when planning for retirement and gives her advice for retirement planning amid market uncertainty.

    from Yahoo Finance https://ift.tt/3hFpY8p

  • Pelosi against extra jobless benefits temporary extension

    Pelosi against extra jobless benefits temporary extensionEvercore ISI Head of U.S. Public Policy and Political Strategy Research Sarah Bianchi joins Yahoo Finance’s Akiko Fujita to discuss the latest stimulus negotiations in Congress, as Republicans delay the unveiling of their $1 trillion stimulus plan to next week.

    from Yahoo Finance https://ift.tt/2BstXWe

  • The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

    The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer EarningsBiotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.Although there were promising updates from some coronavirus vaccine makers, negative headlines plagued Novavax, Inc. (NASDAQ: NVAX) and Moderna Inc (NASDAQ: MRNA), sending their stocks lower by 4.7% and 23%, respectively, for the week.The week saw the listing of 4 biopharma companies on the Nasdaq, which raised a combined $772.9 million.Here are the key catalysts for the unfolding week.Conferences: Alzheimer's Association International Conference, or AAIC, to be held virtually: July 27-31PDUFA Dates The FDA is set to rule on Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) NDA for UX007, its investigational drug for long-chain fatty acid oxidation disorders. (Friday)GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has a PDUFA action date, with the FDA due to announce its verdict on the company's sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex. (Friday)Clinical Readouts AAIC Presentations: Alector Inc (NASDAQ: ALEC): preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia (Tuesday)Eisai Co., Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB): latest data of the investigational anti-amyloid beta protofibril antibody BAN2401; Biogen will also make an oral presentation of the previously publicized topline results of Phase III studies EMERGE and ENGAGEAC Immune SA (NASDAQ: ACIU): Key data on its alpha-synuclein-positron emission tomography tracer program along with a second oral presentation of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndromeSee Also: How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine ProgramStandalone releases: Tcr2 Therapeutics Inc (NASDAQ: TCRR) said it plans to discuss initial data from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors. (before the market open, Monday)Genocea Biosciences Inc (NASDAQ: GNCA) is scheduled to present initial clinical data on the first 5 patients from Part B of the Phase 1/2 study, which is exploring the combination of GEN-009 and immune checkpoint inhibitor-based regimens in advanced solid tumors. (Friday)Pending mid-2020 Releases: Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI): top-line results from Cohort 2 of the ZENITH20 trial evaluating poziotinib in previously treated HER2 non-small cell lung cancer patientsIntra-Cellular Therapies Inc (NASDAQ: ITCI): top-line results from a Phase 3 study evaluating lumateperone as adjunctive therapy in bipolar depression.BioXcel Therapeutics Inc (NASDAQ: BTAI): top-line results from a Phase 1/2b trial of BXCL501 for the acute treatment of agitation associated with geriatric dementia.Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): top-line results from the ILLUMINATE-B Phase 3 study of lumasiran in primary hyperoxaluria type 1 patients less than six years of age with preserved renal function.Karuna Therapeutics Inc (NASDAQ: KRTX): data from Phase 1b clinical trial of KarXT in experimentally induced painAkari Therapeutics PLC (NASDAQ: AKTX): interim update on the Part B placebo-controlled efficacy arm of the study of nomacopan eye drops in atopic keratoconjunctivitisSeres Therapeutics Inc (NASDAQ: MCRB): Data from SER-109 Phase 3 study in recurrent C. difficile infectionMesoblast (NASDAQ: MESO): data from a Phase 3 randomized controlled trial of Revascor for advanced heart failureAkebia Therapeutics Inc (NASDAQ: AKBA: ) top-line data from the global Phase 3 studies evaluating the safety and efficacy of vadadustat in adult patients not on dialysis with anemia due to chronic kidney diseaseView more earnings on IBBAnavex Life Sciences Corp (NASDAQ: AVXL): top-line results from the Phase 2 study of ANAVEX 2-73 in Parkinson's disease dementia Phase 2 trialBIOLINERX LTD/S ADR (NASDAQ: BLRX): Progression-free survival and overall survival data from the triple combination arm of the COMBAT/KEYNOTE-202 Phase 2a study of BL-8040 in combination with Merck & Co., Inc.'s (NYSE: MRK) Keytruda in advanced second-line pancreatic cancerArcus Biosciences Inc (NYSE: RCUS): preliminary data from Phase 1b expansion trials involving combinations with AB928 in multiple tumor types and settingsHomology Medicines Inc (NASDAQ: FIXX): additional data from Phase 1/2 pheNIX gene therapy trial for phenylketonuriaVaxart Inc (NASDAQ: VXRT): data from universal Influenza vaccine collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen unitAlbireo Pharma Inc (NASDAQ: ALBO): top-line results from the Phase 3 PEDFIC 1 trial that is evaluating Odevixibat in progressive familial intrahepatic cholestasis; top-line data from the Phase 3 trial of elobixibat in non-alcoholic steatohepatitis and non-alcoholic fatty liver diseaseresTORbio, Inc. (NASDAQ: TORC): data from the four completed cohorts of the Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson's diseaseEarnings Monday Medpace Holdings Inc (NASDAQ: MEDP) (after the close)Tuesday Exagen Inc (NASDAQ: XGN) (before the market open) Pfizer Inc. (NYSE: PFE) (before the market open) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open) Masimo Corporation (NASDAQ: MASI) (after the close) AtriCure Inc. (NASDAQ: ATRC) (after the close) Amgen, Inc. (NASDAQ: AMGN) (after the close) NeoGenomics, Inc. (NASDAQ: NEO) (after the close) DexCom, Inc. (NASDAQ: DXCM) (after the close) Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close)Wednesday Boston Scientific Corporation (NYSE: BSX) (before the market open) United Therapeutics Corporation (NASDAQ: UTHR) (before the market open) Hologic, Inc. (NASDAQ: HOLX) (after the close) Alimera Sciences Inc (NASDAQ: ALIM) (after the close) Merit Medical Systems, Inc. (NASDAQ: MMSI) (after the close)Thursday Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (before the market open) Blueprint Medicines Corp (NASDAQ: BPMC) (before the market open) Iradimed Corp (NASDAQ: IRMD) (before the market open) •Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) before the market open) Agios Pharmaceuticals Inc (NASDAQ: AGIO) (before the market open) Eli Lilly And Co (NYSE: LLY) (before the market open) Elanco Animal Health Inc (NYSE: ELAN) (before the market open) Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) BioTelemetry Inc (NASDAQ: BEAT) (after the close) MacroGenics Inc (NASDAQ: MGNX) (after the close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (after the close) Emergent Biosolutions Inc (NYSE: EBS) (after the close) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) (after the close) Anika Therapeutics Inc (NASDAQ: ANIK) (after the close) Gilead Sciences, Inc. (NASDAQ: GILD) (after the close) Natus Medical Inc (NASDAQ: NTUS) (after the close) Retrophin Inc (NASDAQ: RTRX) (after the close) Veracyte Inc (NASDAQ: VCYT) (after the close) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) (after the close) Globus Medical Inc (NYSE: GMED) (after the close) Quidel Corporation (NASDAQ: QDEL) (after the close) EXACT Sciences Corporation (NASDAQ: EXAS) (after the close) Tandem Diabetes Care Inc (NASDAQ: TNDM) (after the close)Friday AbbVie Inc (NYSE: ABBV) (before the market open) ImmunoGen, Inc. (NASDAQ: IMGN) (before the market open)IPOs Cambridge, Massachusetts-based AlloVir, which develops allogenic off-the-shelf virus-specific T cell therapy candidates targeting 12 devastating viruses, proposes to offer 14.75 million shares in an IPO, with the price range estimated between $16 and $18. The company has applied for listing its shares on the Nasdaq under the ticker symbol ALVR.Woodcliff Lake, New Jersey-based PaxMedica, Inc. has filed with the SEC to offer 2.5 million shares to be priced between $5.50 and $6.50. The company is an early clinical-stage biopharma focusing on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder, and Fragile X syndrome tremor-ataxia. It has applied for listing its shares on the Nasdaq under the ticker symbol PXMD.See more from Benzinga * The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs * The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results * The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    from Yahoo Finance https://ift.tt/2P1bQK0